Respiratory Syncytial Virus study: RSVpreF Vaccine
Official title A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults
ClinicalTrials.gov ID: NCT07768345
What this study is testing
What is RSVpreF Vaccine?
An investigational vaccine being studied to protect immunocompromised adults from Respiratory Syncytial Virus (RSV).
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study will check how safe and well the vaccine works when given again after 1, 2, or 3 years.
- Who it's for
- Adults 18 or older who have a weakened immune system and may or may not have had the RSV vaccine before.
- What's involved
- Participants will receive one arm shot of the RSV vaccine and will have several visits for health checks and blood tests.
- Time commitment
- The study lasts about 12 months and requires at least four visits to the clinic.
- Phase 3: a large, late-stage study
- Time commitment: about 12 months
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Group 1 will include participants naïve to any RSV vaccine.
- Group 2 will include participants who received a single prior dose of RSVpreF (Abrysvo) approximately 1 year (9 to 15 months) prior to enrollment.
- Group 3 will include participants who received a single prior dose of RSVpreF (Abrysvo) approximately 2 years (21 to 27 months) prior to enrollment.
- Group 4 will include participants who previously received 2 doses of RSVpreF in Study C3671023 Substudy B approximately 3 years (36 to 42 months)...
- Participants should have a life expectancy ≥12 months (365 days) in the opinion of the investigator at enrollment. Key
You likely can't join if
- Prior history of any subtype of Guillain-Barré Syndrome (GBS) of any etiology.
- History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any components of the study...
- Participants with a history of transplant rejection, or PTLD, or participants who have had treatment for these conditions, within 90 days prior to...
- Receipt of B-cell depleting therapies within 180 days prior to initial study vaccination. Refer to the study contact for further eligibility details.
The study team makes the final eligibility decision.
Where it is enrolling
- Los Angeles, California, United States
- Washington D.C., District of Columbia, United States
- Decatur, Georgia, United States
- Iowa City, Iowa, United States
- Baltimore, Maryland, United States
- St Louis, Missouri, United States
- New York, New York, United States
- Rochester, New York, United States
- Duncansville, Pennsylvania, United States
- DeSoto, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The study runs about 12 months per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Los Angeles, California, United States; Washington D.C., District of Columbia, United States; Decatur, Georgia, United States; Iowa City, Iowa, United States; Baltimore, Maryland, United States; St Louis, Missouri, United States and 4 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.